Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stanford V Chemotherapy With or Without Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma
NCT00846742Phase 2Active, not recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Jun 2009
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin, vinblastine, mechlorethamine, vincristine sulfate liposome injection, bleomycin and 2 more in Hodgkin lymphoma (HL), sponsored by St. Jude Children's Research Hospital. Primary endpoint: Complete Response Rate at 8 weeks. Started Jun 2009; status: active, not recruiting.
02
Drugs
pegylated liposomal doxorubicinvinblastinemechlorethaminevincristine sulfate liposome injectionbleomycin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00846742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00846742.